Literature DB >> 18026134

Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.

P J Kaplan-Lefko1, B W Sutherland, A I Evangelou, D L Hadsell, R J Barrios, B A Foster, F Demayo, N M Greenberg.   

Abstract

The insulin-like growth factor-1 (IGF-1) signaling axis is important for cell growth, differentiation and survival and increased serum IGF is a risk factor for prostate and other cancers. To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells. This encodes a mature isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid deletion in the N terminus. Expression of IGF-1(des) was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year. Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice. While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1(des) in poorly differentiated primary tumors or metastatic lesions. Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age. These data suggest that increased physiologic levels of IGF-1 facilitate the emergence of hyperplastic lesions while imposing a strong IGF-1-dependent differentiation block. Selection against IGF-1 action appears requisite for progression of localized disease and metastogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026134     DOI: 10.1038/sj.onc.1210943

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

2.  The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion.

Authors:  Swadesh K Das; Anjan K Pradhan; Praveen Bhoopathi; Sarmistha Talukdar; Xue-Ning Shen; Devanand Sarkar; Luni Emdad; Paul B Fisher
Journal:  Cancer Res       Date:  2018-03-23       Impact factor: 12.701

Review 3.  Role of interleukins, IGF and stem cells in BPH.

Authors:  Ian D McLaren; Travis J Jerde; Wade Bushman
Journal:  Differentiation       Date:  2011-08-23       Impact factor: 3.880

4.  Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.

Authors:  Erin Muhlbradt; Jing Ma; Gianluca Severi; Elizabeth Ortner; Vanessa Hayes; Hoa N Hoang; Meir Stampfer; Graham Giles; Michael Pollak; Edward P Gelmann
Journal:  Genes Cancer       Date:  2013-11

5.  Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor.

Authors:  Kuo-Pao Lai; Shinichi Yamashita; Spencer Vitkus; Chih-Rong Shyr; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2011-12-01

6.  Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia.

Authors:  Alana M Hahn; Jason D Myers; Eliza K McFarland; Sanghee Lee; Travis J Jerde
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

7.  Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model.

Authors:  Shuang Wang; Ning Wang; Bin Yu; Mingxing Cao; Yanlong Wang; Yuqi Guo; Yanli Zhang; Ping Zhang; Xiao Yu; Shujing Wang; Li Zeng; Bin Liang; Xin Li; Yingjie Wu
Journal:  Oncogene       Date:  2019-07-16       Impact factor: 9.867

8.  Developmental and oncogenic effects of insulin-like growth factor-I in Ptc1+/- mouse cerebellum.

Authors:  Mirella Tanori; Melissa Santone; Mariateresa Mancuso; Emanuela Pasquali; Simona Leonardi; Vincenzo Di Majo; Simonetta Rebessi; Anna Saran; Simonetta Pazzaglia
Journal:  Mol Cancer       Date:  2010-03-09       Impact factor: 27.401

Review 9.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

Review 10.  Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Authors:  Shazia Irshad; Cory Abate-Shen
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.